The direct receptor-ligand interactions, expressing co-inhibitory ligands like programmed death-ligand 1 (PD-L1), inhibit CD8+ tumour-infiltrating lymphocytes’ function through programmed death-1 (PD-1). The gene discussed is CD8A; the disease is neoplasm.